Statistics

Total Visits

Views
Consistent benefit survival with cabazitaxel (CBZ) in metastatic castration resistant prostate cancer (mCRPC) in Spain: Updated results77

Select a period of time:

Number of views in the range

Views
Consistent benefit survival with cabazitaxel (CBZ) in metastatic castration resistant prostate cancer (mCRPC) in Spain: Updated results42

Views

Views
April 20252
May 20252
June 20254
July 202526
August 20250
September 20253
October 20255
Download CSV file
 untranslated
 untranslated

Top country views

Views
United States20
Brazil11
United Kingdom6
Argentina1
Spain1
Guatemala1
Tunisia1
Turkey1
 

Top cities views

Views
Anchorage1
Buenos Aires1
Caruaru1
Chebba1
Clifton1
Council Bluffs1
Dallas1
Dunoon1
Duque de Caxias1
Formiga1